MCID: RNL011
MIFTS: 48

Renal Osteodystrophy

Categories: Bone diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Osteodystrophy

MalaCards integrated aliases for Renal Osteodystrophy:

Name: Renal Osteodystrophy 12 73 54 15 17 70 32
Renal Rickets 12 73 20 70
Chronic Kidney Disease-Mineral and Bone Disorder 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13068
ICD9CM 34 588.0
MeSH 44 D012080
NCIt 50 C114827
SNOMED-CT 67 266617009
ICD10 32 N25.0
UMLS 70 C0035086 C1527410

Summaries for Renal Osteodystrophy

MalaCards based summary : Renal Osteodystrophy, also known as renal rickets, is related to osteitis fibrosa and osteomalacia. An important gene associated with Renal Osteodystrophy is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Osteoclast differentiation. The drugs Sevelamer and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic... more...

Related Diseases for Renal Osteodystrophy

Diseases related to Renal Osteodystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 osteitis fibrosa 31.7 PTH FGF23 CASR CALCA BGLAP
2 osteomalacia 30.9 VDR PTH FGF23 CASR CALCA BGLAP
3 rickets 30.7 VDR PTH FGF23 CASR BGLAP
4 metabolic acidosis 30.5 PTH FGF23 BGLAP
5 spondyloarthropathy 30.5 TNFSF11 SLPI CALCA
6 fibrous dysplasia 30.3 TNFSF11 FGF23 CALCA BGLAP
7 vitamin d-dependent rickets 30.3 VDR PTH BGLAP
8 end stage renal disease 30.2 VDR PTH MGP FGF23 CASR
9 hypophosphatemia 30.2 VDR PTH FGF23 BGLAP
10 uremia 30.1 VDR TNFRSF11B PTH MGP CASR
11 hyperphosphatemia 30.1 VDR PTH MGP FGF23 CASR BGLAP
12 hyperostosis 30.1 TNFRSF11B SOST FGF23
13 hypophosphatasia 30.1 SLPI PTH FGF23 BGLAP
14 secondary hyperparathyroidism 30.0 VDR TNFRSF11B SLPI PTH FGF23 CASR
15 graves disease 1 30.0 PTH CALCA
16 pseudohypoparathyroidism 30.0 PTH CALCA BGLAP
17 differentiated thyroid carcinoma 30.0 VDR TNFRSF11B BGLAP
18 hyperparathyroidism 30.0 VDR TNFSF11 TNFRSF11B SLPI PTH FGF23
19 osteomyelitis 30.0 TNFSF11 CALCA ACP5
20 calcinosis 29.9 MGP FGF23 CALCA
21 periapical periodontitis 29.9 TNFSF11 ACP5
22 osteonecrosis 29.9 TNFSF11 TNFRSF11B PTH BGLAP ACP5
23 otosclerosis 29.9 VDR TNFRSF11B CALCA
24 hypoparathyroidism 29.8 VDR PTH FGF23 CASR CALCA BGLAP
25 hypercalcemia, infantile, 1 29.8 VDR PTH CASR CALCA
26 kidney disease 29.8 VDR TNFRSF11B SLPI PTH MGP FGF23
27 spondyloarthropathy 1 29.8 TNFSF11 TNFRSF11B PTH BGLAP
28 synovitis 29.7 TNFSF11 TNFRSF11B ACP5
29 periodontitis 29.6 VDR TNFSF11 BGLAP ACP5
30 hyperthyroidism 29.6 PTH CALCA BGLAP ACP5
31 mammary paget's disease 29.5 TNFSF11 TNFRSF11B PTH CALCA BGLAP ACP5
32 bone disease 29.5 VDR TNFSF11 TNFRSF11B SOST SLPI PTH
33 sclerosteosis 29.4 VDR TNFSF11 SOST PTH BGLAP
34 bone resorption disease 29.4 VDR TNFSF11 TNFRSF11B SOST PTH FGF23
35 hypocalcemia, autosomal dominant 1 29.4 VDR PTH FGF23 CASR CALCA BGLAP
36 osteopetrosis 29.3 TNFSF11 TNFRSF11B CALCA BGLAP ACP5
37 calciphylaxis 29.2 VDR PTH MGP FGF23 CASR
38 glucocorticoid-induced osteoporosis 28.9 VDR TNFSF11 TNFRSF11B PTH CALCA BGLAP
39 primary hyperparathyroidism 28.8 VDR TNFSF11 SOST PTH IGFBP1 FGF23
40 brittle bone disorder 28.7 TNFSF11 TNFRSF11B SOST PTH CALCA BGLAP
41 paget's disease of bone 28.6 VDR TNFSF11 TNFRSF11B SOST PTH CASR
42 chronic kidney disease 28.0 VDR TNFSF11 TNFRSF11B SOST SLPI PTH
43 osteoporosis 26.4 VDR TNFSF11 TNFRSF11B SOST SLPI PTH
44 bone inflammation disease 10.8
45 arterial calcification, generalized, of infancy, 1 10.4
46 hypocalciuric hypercalcemia, familial, type i 10.3 PTH CASR
47 hypocalciuric hypercalcemia, familial, type ii 10.3 PTH CASR
48 hypocalciuric hypercalcemia, familial, type iii 10.3 PTH CASR
49 dental pulp necrosis 10.3 TNFSF11 BGLAP
50 hypercalciuria, absorptive, 2 10.3 VDR CASR

Comorbidity relations with Renal Osteodystrophy via Phenotypic Disease Network (PDN):


Acute Cystitis Acute Kidney Failure
Chronic Kidney Disease Deficiency Anemia
Heart Disease Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Renal Osteodystrophy:



Diseases related to Renal Osteodystrophy

Symptoms & Phenotypes for Renal Osteodystrophy

GenomeRNAi Phenotypes related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.09 IGFBP4 IGFBP5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-106 10.09 IGFBP5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.09 IGFBP4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.09 IGFBP5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 10.09 BGLAP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 10.09 IGFBP1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 10.09 IGFBP1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-133 10.09 IGFBP4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.09 TNFSF11
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 10.09 TNFSF11
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 10.09 MGP
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.09 MGP
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.09 MGP
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.09 BGLAP
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 10.09 MGP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 10.09 TNFSF11
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.09 BGLAP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.09 MGP TNFSF11
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.09 BGLAP
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 10.09 IGFBP1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 10.09 IGFBP5
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.09 MGP
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.09 MGP
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-24 10.09 IGFBP5
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 10.09 IGFBP5
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.09 IGFBP4
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 10.09 TNFSF11
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.09 IGFBP5
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.09 MGP
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 10.09 IGFBP4
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-76 10.09 MGP
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.09 IGFBP5
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.09 MGP
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.09 MGP
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-90 10.09 MGP
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.09 TNFSF11

MGI Mouse Phenotypes related to Renal Osteodystrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 BGLAP CASR FGF23 IGFBP4 IGFBP5 MGP
2 endocrine/exocrine gland MP:0005379 9.86 BGLAP CASR FGF23 IGFBP4 IGFBP5 PTH
3 limbs/digits/tail MP:0005371 9.43 FGF23 PTH SOST TNFRSF11B TNFSF11 VDR
4 skeleton MP:0005390 9.28 BGLAP CASR FGF23 MGP PTH SOST

Drugs & Therapeutics for Renal Osteodystrophy

Drugs for Renal Osteodystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Zoledronic Acid Approved Phase 4 118072-93-8 68740
3
Pamidronate Approved Phase 4 40391-99-9 4674
4
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
5
sodium fluoride Approved Phase 4 7681-49-4
6
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
10 Hormones Phase 4
11 1 alpha-hydroxyergocalciferol Phase 4
12 Nutrients Phase 4
13 Trace Elements Phase 4
14 Micronutrients Phase 4
15 Vasoconstrictor Agents Phase 4
16 Vitamins Phase 4
17 Calciferol Phase 4
18 Diphosphonates Phase 4
19 Vitamin D2 Phase 4
20 Ergocalciferols Phase 4
21 Calcium, Dietary Phase 4
22 Protective Agents Phase 4
23 Anti-Infective Agents, Local Phase 4
24 Fluorides Phase 4
25 Listerine Phase 4
26 Anti-Infective Agents Phase 4
27
Calcium Nutraceutical Phase 4 7440-70-2 271
28
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
29
Calcium carbonate Approved, Investigational Phase 3 471-34-1
30
Calcium acetate Approved, Investigational Phase 3 62-54-4
31
carbamide peroxide Approved Phase 3 124-43-6
32
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 5283731 6433735
33
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
34 Chelating Agents Phase 3
35 Pharmaceutical Solutions Phase 3
36 Hydroxycholecalciferols Phase 3
37
Nicotinamide Approved, Investigational Phase 1, Phase 2 98-92-0 936
38
Denosumab Approved Phase 2 615258-40-7
39
tannic acid Approved Phase 2 1401-55-4
40
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
42
Niacin Approved, Investigational, Nutraceutical Phase 1, Phase 2 59-67-6 938
43 Vitamin B9 Phase 1, Phase 2
44 Vasodilator Agents Phase 1, Phase 2
45 Antimetabolites Phase 1, Phase 2
46 Vitamin B Complex Phase 1, Phase 2
47 Lipid Regulating Agents Phase 1, Phase 2
48 Folate Phase 1, Phase 2
49 Nicotinic Acids Phase 1, Phase 2
50 Vitamin B3 Phase 1, Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
2 A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation Completed NCT01675089 Phase 4 Zoledronic acid
3 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
4 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
5 Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease Not yet recruiting NCT04522622 Phase 4 Teriparatide
6 VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome Unknown status NCT00752401 Phase 3 Cholecalciferol;Placebo
7 Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis Unknown status NCT03202407 Phase 3 Calcium acetate and sevelamer hydrochloride
8 The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial Enrolling by invitation NCT04750460 Phase 3 Teriparatide
9 Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis Completed NCT00004340 Phase 2 calcitriol;growth hormone
10 The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Completed NCT00508885 Phase 1, Phase 2 Niacinamide;Placebo
11 A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00527085 Phase 2 AMG 073;Placebo
12 Regulation of Bone Formation in Renal Osteodystrophy Completed NCT00560300 Phase 2 1 alpha D2;1,25 dihydroxy vitamin D3;Sevelamer HCl;Calcium Carbonate
13 A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder Completed NCT01414114 Phase 2 Etelcalcetide
14 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
15 The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients Recruiting NCT03960554 Phase 2 Denosumab Inj 60 mg/ml
16 A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism Terminated NCT01576146 Phase 2 Etelcalcetide
17 Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy Withdrawn NCT01665651 Phase 2 Yougui granules;Zuogui granules;Yougui granules placebo;Zuogui granules placebo
18 Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Unknown status NCT02556216
19 The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients Unknown status NCT01382966
20 Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters Unknown status NCT02708368
21 A Correlation Between Histological Findings of the Blood Vessels in Patients With Chronic Renal Failure and Serum Uremic Toxins and Its Diagnostic Performance in the Assessment of the Cardiovascular Morbidity and Mortality Completed NCT00412139
22 Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD Completed NCT00364234
23 Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD Completed NCT00285467 doxercalciferol;Cholecalciferol
24 Renal Osteodystrophy: A Fresh Approach Completed NCT00859612
25 Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study Completed NCT03464149
26 Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk Completed NCT02697578
27 Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry Recruiting NCT03716128
28 To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI Recruiting NCT04564924
29 Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies Recruiting NCT03285854
30 Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study Recruiting NCT03937349
31 Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey Recruiting NCT04714918
32 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease Recruiting NCT04019379
33 Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages Recruiting NCT02147782
34 Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5 Recruiting NCT04013139
35 Renal Osteodystrophy: A Fresh Approach Active, not recruiting NCT02440581 Alendronate;Teriparatide;Cinacalcet
36 Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease Active, not recruiting NCT03108222
37 Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease Active, not recruiting NCT03626246
38 Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients Terminated NCT00374712

Search NIH Clinical Center for Renal Osteodystrophy

Cochrane evidence based reviews: chronic kidney disease-mineral and bone disorder

Genetic Tests for Renal Osteodystrophy

Anatomical Context for Renal Osteodystrophy

MalaCards organs/tissues related to Renal Osteodystrophy:

40
Bone, Kidney, Liver, Bone Marrow, Cortex, Spinal Cord, Pancreas

Publications for Renal Osteodystrophy

Articles related to Renal Osteodystrophy:

(show top 50) (show all 2305)
# Title Authors PMID Year
1
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. 61 54
19050056 2009
2
PHEX, FGF23, DMP1 and beyond. 61 54
18660670 2008
3
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. 54 61
16117195 2005
4
Parathyroid hormone decreases renal vitamin D receptor expression in vivo. 61 54
15769857 2005
5
Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. 54 61
16686316 2005
6
Osteoprotegerin and bone mineral density in hemodiafiltration patients. 61 54
16152990 2005
7
Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients. 61 54
15665550 2005
8
Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. 61 54
15199292 2004
9
Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 61 54
15631342 2004
10
Correlations of new markers of bone formation and resorption in kidney transplant recipients. 61 54
12826157 2003
11
Musculoskeletal manifestations of chronic renal failure. 54 61
12496510 2003
12
Pathogenesis and treatment of renal osteodystrophy. 61 54
12944733 2003
13
Increased levels of osteoprotegerin in hemodialysis patients. 61 54
12476941 2002
14
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 61 54
11877577 2002
15
Calcitonin as a helper of calcitriol therapy in renal osteodystrophy. 54 61
11096303 2000
16
Calcium supplement necessary to correct hypocalcemia after total parathyroidectomy for renal osteodystrophy. 54 61
10710245 2000
17
Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts. 54 61
10657717 2000
18
Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. 54 61
10652019 2000
19
Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. 61 54
10077343 1999
20
Characteristics of biochemical markers in patients with metabolic bone disorders. 54 61
9553754 1998
21
Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. 61 54
9127327 1997
22
Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. 54 61
8704118 1996
23
Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy? 61 54
8559512 1995
24
Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. 54 61
7724029 1995
25
Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. 54 61
7865545 1994
26
Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. 54 61
8258962 1993
27
[Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure]. 61 54
1808343 1991
28
Endosteal surfaces in hyperparathyroidism: an enzyme cytochemical study on low-temperature-processed, glycol-methacrylate-embedded bone biopsies. 61 54
1750188 1991
29
[Diagnostic evaluation of plasma free gamma-carboxyglutamic acid in maintenance hemodialytic patients with renal osteodystrophy]. 54 61
2082053 1990
30
Measurement of serum bone gla-protein (BGP) in humans with an ovine BGP-based radioimmunoassay. 61 54
2208702 1990
31
Osteocalcin, iPTH, alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. 61 54
2077408 1990
32
The Role of Bone Biopsy in the Management of CKD-MBD. 61
33772341 2021
33
The French multicentre elevated bone mass study: prevalence and causes. 61
33655400 2021
34
Use of a Phosphorus Points Education Program to Maintain Normal Serum Phosphorus in Pediatric Chronic Kidney Disease: A Case Report. 61
32747032 2021
35
Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. 61
33774081 2021
36
Oral health in children with chronic kidney disease. 61
33528633 2021
37
Vitamin D supplements: The pharmacists' perspective. 61
33674204 2021
38
Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. 61
33091638 2021
39
The Non-invasive Diagnosis of Bone Disorders in CKD. 61
33398414 2021
40
The role of static bone histomorphometry in diagnosing renal osteodystrophy. 61
33065356 2021
41
A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures. 61
33430788 2021
42
CKD-MBD post kidney transplantation. 61
31858226 2021
43
Old and New Drugs for the Management of Bone Disorders in CKD. 61
33386480 2021
44
Nonunion of the coracoid process: a systematic review. 61
33125544 2020
45
Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis. 61
32654892 2020
46
A loosening prosthesis in a dialysis patient. 61
33123365 2020
47
18F-Fluorocholine PET/CT, Tc-99m-MIBI and TC-99m-MDP SPECT/CT in Tertiary Hyperparathyroidism with Renal Osteodystrophy. 61
33092198 2020
48
Stress Fracture of Bilateral Neck of Femur in a Healthy Non-athletic Young Adult - A Case Report With Review of Literature. 61
33269124 2020
49
Prevalence and causes of elevated bone mass. 61
32534222 2020
50
The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. 61
32422129 2020

Variations for Renal Osteodystrophy

Expression for Renal Osteodystrophy

Search GEO for disease gene expression data for Renal Osteodystrophy.

Pathways for Renal Osteodystrophy

GO Terms for Renal Osteodystrophy

Cellular components related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TNFSF11 TNFRSF11B SOST SLPI PTH IGFBP5
2 endoplasmic reticulum lumen GO:0005788 9.55 IGFBP5 IGFBP4 IGFBP1 FGF23 BGLAP
3 extracellular region GO:0005576 9.4 TNFSF11 TNFRSF11B SOST SLPI PTH MGP

Biological processes related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.89 IGFBP5 IGFBP4 IGFBP1 FGF23
2 animal organ morphogenesis GO:0009887 9.8 VDR TNFSF11 FGF23
3 aging GO:0007568 9.78 IGFBP5 IGFBP1 CALCA BGLAP
4 skeletal system development GO:0001501 9.73 VDR TNFRSF11B PTH BGLAP
5 cellular calcium ion homeostasis GO:0006874 9.71 VDR PTH CASR CALCA
6 cellular protein metabolic process GO:0044267 9.65 IGFBP5 IGFBP4 IGFBP1 FGF23 CALCA
7 calcium ion homeostasis GO:0055074 9.63 TNFSF11 PTH
8 vasodilation GO:0042311 9.62 CASR CALCA
9 negative regulation of ossification GO:0030279 9.61 SOST CALCA
10 response to vitamin D GO:0033280 9.61 PTH BGLAP
11 negative regulation of bone resorption GO:0045779 9.6 TNFRSF11B CALCA
12 regulation of osteoclast differentiation GO:0045670 9.58 TNFSF11 BGLAP
13 response to inorganic substance GO:0010035 9.58 TNFRSF11B BGLAP
14 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.57 IGFBP5 IGFBP4
15 vitamin D metabolic process GO:0042359 9.56 VDR FGF23
16 response to magnesium ion GO:0032026 9.55 TNFRSF11B FGF23
17 type B pancreatic cell proliferation GO:0044342 9.54 IGFBP5 IGFBP4
18 bone resorption GO:0045453 9.54 TNFSF11 PTH ACP5
19 cellular response to parathyroid hormone stimulus GO:0071374 9.52 SOST FGF23
20 response to fibroblast growth factor GO:0071774 9.51 PTH CASR
21 regulation of bone mineralization GO:0030500 9.5 MGP FGF23 BGLAP
22 phosphate ion homeostasis GO:0055062 9.49 PTH FGF23
23 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.46 VDR FGF23
24 cellular response to vitamin D GO:0071305 9.33 FGF23 CASR BGLAP
25 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.13 IGFBP5 IGFBP4 IGFBP1
26 ossification GO:0001503 9.1 TNFSF11 SOST MGP CASR BGLAP ACP5

Molecular functions related to Renal Osteodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor binding GO:0019838 9.5 IGFBP5 IGFBP4 IGFBP1
2 insulin-like growth factor binding GO:0005520 9.33 IGFBP5 IGFBP4 IGFBP1
3 structural constituent of bone GO:0008147 9.26 MGP BGLAP
4 insulin-like growth factor I binding GO:0031994 9.13 IGFBP5 IGFBP4 IGFBP1
5 insulin-like growth factor II binding GO:0031995 8.8 IGFBP5 IGFBP4 IGFBP1

Sources for Renal Osteodystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....